|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||38.03 - 38.25|
|52 Week Range||29.45 - 38.32|
|Beta (3Y Monthly)||0.43|
|PE Ratio (TTM)||24.91|
|Forward Dividend & Yield||1.07 (2.81%)|
|1y Target Est||40.17|
Celgene (CELG) gets a positive CHMP opinion, recommending the approval of Revlimid in combination with Rituxan for the treatment of adult patients with previously treated FL.
Roche's (RHHBY) breast cancer candidate and lymphona candidate get positive CHMP opinion. The company inks a deal to acquire Promedior, Inc.
— Study results reflect advancements in HER2-positive, triple-negative, and hormone receptor-positive breast cancer —
Study results reflect advancements in HER2-positive, triple-negative, and hormone receptor-positive breast cancerFollow-up data from pivotal phase III APHINITY study evaluating.
LEXINGTON, Mass., Nov. 15, 2019 /PRNewswire/ -- Promedior, Inc., today announced that it has entered into a definitive merger agreement for Roche (SIX: RO, ROG; OTCQX: RHHBY) to acquire Promedior. With this acquisition, Roche will obtain full rights to Promedior's entire portfolio of molecules for serious fibrotic diseases, notably PRM-151.
Kadcyla cut the risk of disease recurrence or death by half compared to Herceptin in the adjuvant setting for specific patients with HER2-positive early breast cancer At three.
Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the EU Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for Polivy® (polatuzumab vedotin) in combination with bendamustine plus MabThera® (rituximab) (BR) for the treatment of adults with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL), who are not candidates for a haematopoietic stem cell transplant. “People with relapsed or refractory diffuse large B-cell lymphoma have limited treatment options – especially those who are not candidates for haematopoietic stem cell transplant,” said Levi Garraway, MD, PhD, Roche’s Chief Medical Officer and Head of Global Product Development.
Dollar trading volume on OTC Markets topped $29 billion in October, approximately a 4.5% increase from September. For the month, total dollar volume on the OTCQX Market, the top tier of OTC Markets, was ...
Halozyme (HALO) reports lower-than-expected earnings and revenues in third-quarter 2019. It lowers the sales outlook for 2019 and raises the same for operating expenses.
Bristol-Myers' (BMY) label expansion application for Opdivo plus Yervoy combo regimen to include patients with hepatocellular carcinoma, a form of liver cancer, makes progress.
AbbVie (ABBV) submits a regulatory application with the FDA seeking label expansion of Imbruvica as a first-line treatment for chronic lymphocytic leukemia in combination with Roche's Rituxan.
Roche's bid to rival Biogen and Novartis in treating spinal muscular atrophy (SMA) got a lift on Monday when the Swiss drugmaker said its drug risdiplam improved motor function of patients in a key study. Roche, which plans to seek approval for the investigational medicine this year, said its SUNFISH trial demonstrated statistically significant improvements in patients aged 2-25 years with Type 2 or 3 SMA, compared to a placebo. Biogen's Spinraza, approved in 2016, lists at $750,000 in year one and $375,000 thereafter, while Novartis's Zolgensma is the costliest one-time treatment at $2.1 million.
This week, Salesforce held their annual Dreamforce conference in San Francisco. Yahoo Finance’s Julia La Roche joins On the Move to break down what Salesforce Co-CEO Keith Block had to say about deploying disruptive technology in ethical ways.
Salesforce's annual conference, Dreamforce, has taken over the Bay Area. Yahoo Finance's Julia LaRoche fills in Jen Rodgers and Myles Udland on the latest in big names in the tech world. That includes a fireside chat between Tim Cook and Marc Benioff on a future partnership in the world of IOS apps.
The well-known head of the T-Mobile, John Legere, will step down next year on April 30. The day after, he'll be replaced by Mike Sievert, who is currently president and COO of the company. Yahoo Finance’s Dan Roberts, Julia La Roche and Brian Cheung discuss on YFi AM.
Lyft is scaling back its electric scooters in 7 major cities, including Nashville, Dallas, Phoenix, and Atlanta. Yahoo Finance’s Dan Roberts, Brian Cheung and Julia La Roche discuss Lyft’s pullback on YFi AM.
The C-E-O of Chinese tech company ByteDance, which owns TikTok, is pushing to diversify its audience outside of the US, according to an internal memo obtained by Reuters — this comes as the U-S continues to scrutinize ByteDance over security concerns. The two-year old app TikTok has quickly gained in popularity, with 1.5 billion downloads. As the app has gained favor with teens in the U-S, tensions between Washington and Beijing have escalated.
Walmart reported its Q3 earnings, posting revenues of nearly $128 billion, and adjusted earnings that beat estimates. Yahoo Finance’s Brian Sozzi, Alexis Christoforous, and Julia La Roche discuss the retailer’s big win.
Dirk Van de Put, CEO of Mondelēz International (NASDAQ: MDLZ), talks to Yahoo Finance's Julia La Roche about the company's global strategy and reveals the findings of a recent study about snacking behavior.
Uber is facing a PR disaster after CEO Dara Khosrowshahi told Axios that the killing of American journalist Jamal Khashoggi was "a serious mistake" and then compared it to Uber's own "mistakes" with self-driving experiments. Yahoo Finance’s Dan Roberts, Julia La Roche and Brian Cheung discuss on YFi AM.
Facebook announced that Instagram could begin hiding "likes" on some U.S. accounts as early as this week. Users will still be able to see likes on their own posts, but those counts will not be visible to others viewing your post. Yahoo Finance’s Dan Roberts, Julia La Roche and Brian Cheung discuss on YFi AM.